Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Eur J Cancer ; 50(15): 2592-601, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25096168

ABSTRACT

BACKGROUND: Weekly paclitaxel/carboplatin might improve survival in platinum-resistant epithelial ovarian cancer (EOC). We compared efficacy of first-line weekly to three-weekly paclitaxel/cis- or carboplatin (PCw and PC3w) induction therapy, followed by either three or six PC3w cycles. PATIENTS AND METHODS: In this multicentre, randomised phase III trial with 2×2 design, patients with FIGO stage IIb-IV EOC were randomised to six cycles PCw (paclitaxel 90mg/m(2), cisplatin 70mg/m(2) or carboplatin AUC 4) or three cycles PC3w (paclitaxel 175mg/m(2), cisplatin 75mg/m(2) or carboplatin AUC 6), followed by either three or six cycles PC3w. Primary endpoints were progression free survival (PFS) and overall survival (OS). Secondary endpoints were response rate (RR) and toxicity. RESULTS: Of 267 eligible patients, 133 received PCw and 134 PC3w. The first 105 patients received cisplatin, after protocol amendment the subsequent 162 patients received carboplatin. Weekly cisplatin was less well tolerated than weekly carboplatin. All PC3w cycles were well tolerated. At the end of all treatments, RR was 90.8% with no differences between the treatment arms. After a follow-up of median 10.3years (range 7.1-14.8), median PFS was 18.5 (95% confidence interval (CI) 15.9-21.0) months for PCw and 16.4 (95% CI 13.5-19.2) months for PC3w (p=0.78). Median OS was 44.8 (95% CI 33.1-56.5) months for PCw and 41.1 (95% CI 34.4-47.7) months for PC3w (p=0.98). CONCLUSIONS: There was no benefit in terms of OS, PFS or RR for a weekly regimen nor for extended chemotherapy as first-line treatment for EOC in European patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms, Glandular and Epithelial/drug therapy , Ovarian Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/administration & dosage , Carboplatin/adverse effects , Cisplatin/administration & dosage , Cisplatin/adverse effects , Disease-Free Survival , Drug Administration Schedule , Europe , Fatigue/chemically induced , Female , Follow-Up Studies , Humans , Induction Chemotherapy , Middle Aged , Nausea/chemically induced , Neoplasms, Glandular and Epithelial/pathology , Neutropenia/chemically induced , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Time Factors , Treatment Outcome , Vomiting/chemically induced , Young Adult
3.
Semin Oncol ; 17(6 Suppl 10): 24-7, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2259920

ABSTRACT

A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35, 35+, 42+, 51+, 55+ months) and the partial remission rate was 20%. Median survival for complete responders was more than 4 years. The best responses were seen in patients with relapsed NHL compared to those with primary refractory NHL. Toxicity was mainly related to myelosuppression. The results suggest that the CAMP schedule can be applied on an outpatient basis with satisfactory efficacy in patients with relapsing intermediate- and high-grade malignant NHL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Combined Modality Therapy , Cytarabine/administration & dosage , Doxorubicin/pharmacology , Drug Evaluation , Drug Resistance , Female , Humans , Lomustine/administration & dosage , Lymphoma, Non-Hodgkin/mortality , Male , Middle Aged , Mitoxantrone/administration & dosage , Prednisone/administration & dosage , Remission Induction , Survival Rate
6.
Brain Res ; 128(3): 447-59, 1977 Jun 17.
Article in English | MEDLINE | ID: mdl-884493

ABSTRACT

Reversal of the sign of long ascending and descending spinal reflexes dependent on the phase of the step cycle has been shown in the high decerebrate cat. Electrical stimuli were applied to the skin over the dorsum of the metacarpals and metatarsals and the effects were recorded in the corresponding hindlimb or forelimb of the same side. Stimulation generally evoked an increase in activity of flexor or extensor muscles shortly before, and during, activity of the muscle. Inhibition of a muscle occurred when its activity overlapped with the activity of an antagonist muscle. From the latencies it was concluded that at least the early components of the long reflex responses are due to spinal mechanisms. In the stimulated limb the activity of flexor and extensor muscles was also modulated in a phase dependent manner. No consistent long spinal responses to skin stimulation were obtained in high spinal cats during stepping. Electrical stimulation of cutaneous nerve trunks in decerebrate preparations during stepping gave variable though phase dependent long spinal reflex effects.


Subject(s)
Gait , Muscles/physiology , Spinal Cord/physiology , Animals , Cats , Decerebrate State , Electric Stimulation , Electromyography , Extremities , Posture , Proprioception , Reflex , Skin/innervation
SELECTION OF CITATIONS
SEARCH DETAIL
...